就汇添富稳宏6个月持有期债券型证券投资基金召开基金份额持有人大会事宜，汇添富基金管理股份有 限公司（以下简称"基金管理人"或"本基金管理人"）已于2025年9月11日发布了《汇添富基金管理股份 有限公司关于以通讯方式召开汇添富稳宏6个月持有期债券型证券投资基金基金份额持有人大会的公 告》，为使本次基金份额持有人大会顺利召开，现发布关于召开汇添富稳宏6个月持有期债券型证券投 资基金基金份额持有人大会的第一次提示性公告。 联系人：马兰 根据《中华人民共和国证券投资基金法》（以下简称"《基金法》"）、《公开募集证券投资基金运作管 理办法》和《汇添富稳宏6个月持有期债券型证券投资基金基金合同》（以下简称"《基金合同》"）的 有关规定，汇添富稳宏6个月持有期债券型证券投资基金的基金管理人汇添富基金管理股份有限公司决 定以通讯方式召开汇添富稳宏6个月持有期债券型证券投资基金的基金份额持有人大会，会议的具体安 排如下： （一）会议召开方式：通讯方式 （二）会议投票表决起止时间：自2025年9月15日起，至2025年10月14日17：00止（投票表决时间以基 金管理人收到表决票时间为准）。 （三）会议通讯表决票的送达地点： ...

Core Viewpoint - The second batch of Sci-Tech Innovation Bond ETFs is set to be issued, with rapid expansion in scale enhancing liquidity and pricing efficiency in the market [1][2]. Group 1: Market Expansion and Product Details - As of September 8, 2025, the total scale of the first batch of 10 Sci-Tech Innovation Bond ETFs has exceeded 120 billion yuan, representing a growth of over 300% from the initial fundraising amount [1]. - The second batch consists of 14 Sci-Tech Innovation Bond ETFs, which received approval on September 8, 2025, and will be launched on September 12, 2025 [1]. - The introduction of new products is expected to further enrich investor choices and enhance market liquidity and pricing efficiency, thereby increasing the activity level of the Sci-Tech Innovation Bond ETF market [1]. Group 2: Competitive Landscape and Management Strength - The second batch of Sci-Tech Innovation Bond ETFs will face heightened competition, necessitating stronger capabilities in fixed income management, company empowerment, and ETF operation from the issuers [2]. - Huatai-PineBridge Fund stands out among the issuers, leading in the aforementioned areas. As of the end of Q2 2025, Huatai-PineBridge's assets under management exceeded 1 trillion yuan, with bond fund assets surpassing 260 billion yuan [2]. - The firm has also achieved an ETF management scale exceeding 100 billion yuan, ranking it among the top issuers in this category [2]. Group 3: Fund Management and Performance - The performance of actively managed pure bond funds in 2025 has shown that short-term bonds outperform medium to long-term bonds, and credit bonds outperform interest rate bonds [12]. - During the recent market adjustment, the decline in the value of Sci-Tech Innovation Bond ETFs was less severe compared to other interest rate bond ETFs, indicating better market resilience [12]. - The liquidity of bond ETFs is expected to continue improving as the current market environment stabilizes [12]. Group 4: Regulatory Changes and Future Opportunities - New sales fee regulations issued by the China Securities Regulatory Commission on September 5, 2025, are anticipated to create greater development opportunities for bond ETFs [17]. - The proposed changes in redemption fees may lead to a shift in institutional investment from interest rate bond funds to bond ETFs, enhancing the latter's growth prospects [17].

Group 1 - The core viewpoint of the article highlights the performance of the Kexin Chip 50 ETF (588750), which opened with a slight increase of 0.23% at 1.332 yuan [1] - The major holdings of the Kexin Chip 50 ETF include companies such as SMIC, Haiguang Information, and Cambrian, with varying performance; for instance, SMIC decreased by 1.24%, while Cambrian increased by 1.73% [1] - The Kexin Chip 50 ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Chip Index, managed by Huatai-PineBridge Fund Management Co., Ltd., with a return of 33.47% since its establishment on December 18, 2024, and a return of 23.61% over the past month [1]

1. Report Industry Investment Rating There is no information provided about the industry investment rating in the report. 2. Core Views of the Report - The second batch of Sci - tech Bond ETFs is about to be issued. It is advisable to select products with top - ranked comprehensive strength in fixed - income management, company empowerment, and ETF operation. Under the new sales fee regulations, bond ETFs are expected to have greater development opportunities [1][3]. - The scale of the first batch of Sci - tech Bond ETFs has expanded rapidly, and the second batch of 14 products will be issued on September 12, 2025, which will further boost the market expansion, enrich investor choices, and improve market liquidity and pricing efficiency [3]. - Since 2025, the coupon strategy has been dominant, and Sci - tech Bond ETFs have shown certain resilience during market adjustments. With the improvement of the market environment, the liquidity of bond ETFs is expected to continue to improve [3]. 3. Summary According to the Directory 3.1. Expansion of Underlying Bonds of Sci - tech Bonds: Continuous Growth in Quantity and Scale - Since the joint release of the relevant announcement by the People's Bank of China and the China Securities Regulatory Commission on May 7, 2025, the supply of sci - tech bonds has been increasing. As of the first half of 2025, 853 sci - tech bonds were issued with a cumulative scale of 989.1 billion yuan. From the beginning of the second half of the year to early September, 459 bonds were issued with a scale of 431.6 billion yuan. This provides a wider selection of underlying bonds for Sci - tech Bond ETFs [7]. - As of September 8, 2025, 42.8% of the remaining maturity of outstanding sci - tech bonds is concentrated in 1 - 3 years, and the average remaining maturity after balance - weighting is about 3.4 years. In the future, the duration of issuance is expected to increase [8]. - As of September 8, 2025, over 85% of the outstanding balance of broad - sense sci - tech bonds is issued by central and local state - owned enterprises, while the proportion of private enterprises has also increased, exceeding 7.2% [8]. 3.2. The Market of Sci - tech Bond ETFs is Expected to Maintain High - level Prosperity 3.2.1. The First Batch of Sci - tech Bond ETFs Performed Well After Listing - The first batch of 10 Sci - tech Bond ETFs were issued on July 7, 2025, with an initial raise of about 29 billion yuan. As of September 8, 2025, the total scale exceeded 120 billion yuan, a growth of over 300% compared to the initial amount, accounting for 21.3% of all bond ETFs [15]. - Since mid - July, the trading of the first batch of Sci - tech Bond ETFs has been active. As of September 8, 2025, the average daily trading volume of some funds exceeded 7 billion yuan, and that of others was above 4 billion yuan [15]. - In 2025, the coupon strategy of credit bonds has shown advantages, and Sci - tech Bond ETFs have shown certain resilience during market adjustments. Their callback amplitude is smaller than that of interest - rate bond ETFs, and they have better secondary - market acceptance [16][22]. 3.2.2. The Second Batch of Sci - tech Bond ETFs is About to be Listed, and the Market is Expected to Expand at an Accelerated Pace - The second batch of 14 Sci - tech Bond ETFs was approved on September 8, 2025, and will be issued on September 12. The participating entities are more diversified, which will accelerate the expansion of the bond ETF market. Sci - tech Bond ETFs will become the largest sub - category in terms of market value [25]. - The three major indices tracked by Sci - tech Bond ETFs have excellent historical returns. The CSI AAA Sci - tech Bond Index has a higher underlying bond capacity, with a cumulative return of 13.29 and an annualized return of 4.89% from the end of 2022 to September 9, 2025 [26]. 3.3. How to Select the Second Batch of Sci - tech Bond ETFs: Three Dimensions and One Variable 3.3.1. The Comprehensive Strength in Fixed - Income Management, Company Empowerment, and ETF Operation Will Determine Success - With the expansion of the Sci - tech Bond ETF market, competition will intensify. The comprehensive strength in fixed - income management, company empowerment, and ETF operation will determine whether a product can stand out [30]. - Among the issuers of the second batch of Sci - tech Bond ETFs, Huatai - PineBridge has strong comprehensive strength. As of the end of the second quarter of 2025, its managed asset scale exceeded 1 trillion yuan, and the scale of bond funds exceeded 260 billion yuan. Its ETF management scale also exceeded 100 billion yuan. It also adopted the T + 1 same - day bond - replenishment model [31]. 3.3.2. Under the New Sales Fee Regulations, Bond ETFs are Expected to Have Greater Development Opportunities - On September 5, 2025, the China Securities Regulatory Commission issued a notice on soliciting opinions on the revised regulations of public - offering fund sales fees. The optimization of the redemption - fee mechanism will have a significant impact on bond funds [38]. - The new regulations require that 100% of the redemption fee be included in the fund property, simplify the redemption - fee schedule to three levels, and cover all bond - fund categories, which will increase the cost of short - term trading [38]. - Calculations show that under the new regulations, redeeming bond funds within six months may not be economically viable. In a low - interest - rate environment, bond ETFs are expected to attract more trading - oriented funds [40][41].

Group 1 - The core point of the news is that Huatai Fund Management Co., Ltd. increased its stake in Sihuan Pharmaceutical (01530.HK) by purchasing 2.092 million shares at an average price of HKD 31.18 per share, totaling approximately HKD 65.23 million [1] - Following this transaction, Huatai Fund's total shareholding in Sihuan Pharmaceutical rose to 122,265,500 shares, increasing its ownership percentage from 4.94% to 5.03% [1][3]

Group 1 - The article provides a ranking of the top 10 open-end funds based on net value growth over a five-day period, highlighting the performance of various funds [2][6] - The top-performing funds include 东方阿尔法产业先锋混合A, 东方阿尔法产业先锋混合C, and 圆信永丰高端制造A, with significant net value increases [2][6] - The article also mentions the bottom-performing funds, such as 天治财富增长混合, which experienced a decline in net value [4][6] Group 2 - The overall market performance shows a rise in the Shanghai Composite Index and the ChiNext Index, with a total trading volume of 2.35 trillion yuan, indicating a bullish market sentiment [6] - Leading sectors include electrical equipment, communication devices, and components, with notable growth in solid-state and sodium battery concepts [6] - The article notes that the fund 东方阿尔法产业先锋混合A has shown rapid net value growth, outperforming the market [6][7]

Group 1 - The core point of the article is that Huatai Fund Management Co., Ltd. has increased its stake in 3SBio Inc. by acquiring 2.092 million shares at a price of HKD 31.18 per share, totaling approximately HKD 65.2286 million [1] - After the acquisition, the total number of shares held by Huatai Fund is approximately 122 million, representing a holding percentage of 5.03% [1]

Group 1 - The core point of the article is that Huatai Fund Management Co., Ltd. has increased its stake in 3SBio Inc. by acquiring 2.092 million shares at a price of HKD 31.18 per share, totaling approximately HKD 65.2286 million [1] - After the increase, the total number of shares held by Huatai Fund is approximately 122 million, representing a holding percentage of 5.03% [1]

Core Insights - The Chinese innovative drug industry is experiencing rapid growth driven by supportive government policies and market opportunities, with the Sci-Tech Innovation Board (STAR Market) playing a crucial role in the development of innovative drug companies [1][2][4] Policy Support - The Chinese government has implemented a comprehensive set of policies to support the development of innovative drugs, including optimizing drug review and approval processes, accelerating clinical applications, and enhancing market access [2][3] - Since the establishment of the National Medical Insurance Bureau, 149 innovative drugs have been included in the medical insurance catalog, with over 360 billion yuan paid for innovative drugs during the agreement period [2][3] - The introduction of a "Category C" medical insurance directory aims to increase the role of commercial health insurance in covering innovative drug costs, providing additional funding sources for innovative drugs [3] Industry Trends - Companies listed on the STAR Market are characterized by high R&D investment and a focus on original innovative drug development, with approximately 70% of the STAR Market innovative drug index constituents being pure innovative drug companies [4][5] - As of the end of 2024, China has a total of 3,575 innovative drug R&D pipelines, surpassing the U.S. and covering about 40% of global new drug development [5] - Many innovative drug companies are entering a commercialization phase, with improved cash flow and profitability, indicating a shift from a reliance on licensing deals to a focus on revenue generation [6] Internationalization - Chinese innovative drug companies are increasingly engaging in international collaborations, with 94 licensing agreements worth a total of 51.9 billion USD in 2024 alone, and over 450 million USD in the first five months of 2025 [7][8] - Chinese companies are gaining recognition on international academic stages, with a record number of clinical studies presented at the ASCO 2025 annual meeting, showcasing the competitiveness of Chinese innovative drugs [8] Investment Opportunities - The Sci-Tech Innovation Drug ETF (subscription code: 589123) offers investors a convenient way to invest in the innovative drug sector, tracking the STAR Market innovative drug index, which has a high purity of innovative drug companies [9] - The index is designed to balance theme purity and risk diversification, with approximately 70% of its constituents being pure innovative drug companies, allowing investors to benefit from the overall growth of the sector [9]

Group 1: Market Performance - The computing power sector rebounded quickly after hitting a low, with the cloud computing ETF Huatai (159273) rising nearly 3% and trading volume exceeding 350 million yuan [1] - The fund has seen continuous inflows for 17 days, with a net inflow of over 4 million yuan on the day, totaling over 1.1 billion yuan in inflows over 20 out of 22 days since its listing [1] Group 2: Industry Insights - The optical module market is expected to experience significant growth, with 800G optical modules starting to ramp up in 2023 and maintaining high growth through 2026, while 1.6T optical modules are anticipated to begin shipping in 2025 [4] - The rapid development of AI is driving an increase in bandwidth capacity, leading to a trend of "optical replacing copper" in the chip interconnection field [4] - The CPO (Chiplet-based Photonic Optics) technology is projected to significantly enhance the market size of optical communication, with a potential shift in the industry towards optical engines [6] Group 3: Company Developments - Alibaba has reported a record high in quarterly capital expenditure for AI and cloud services, launching a new cloud computing chip aimed at handling a broader range of AI inference tasks [8] - The new chip is in the testing phase and is expected to be manufactured by local Chinese firms, enhancing Alibaba's ability to control its computing power supply amid U.S. export restrictions [8] Group 4: Policy and Strategic Developments - The Chinese government has elevated "Artificial Intelligence+" to a national strategy, aiming for significant penetration of AI applications into the economy and society by 2035 [7] - The policy outlines a three-stage development goal, with a target of over 70% application penetration of new intelligent terminals and entities by 2027 [7]